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Abstract
Background: In solid tumors, such as breast cancer, cells are exposed to hypoxia. Cancer cells adapt their metabolism by
activating hypoxia-inducible factors (HIFs) that promote the transcription of genes involved in processes such as cell survival,
drug resistance and metastasis. HIF-1 is also induced in an oxygen-independent manner through the activation of epidermal
growth factor receptor tyrosine kinase (EGFR-TK). Triple-negative breast cancer (TNBC) is a subtype of invasive breast cancer
characterized by negative expression of hormonal and HER2 receptors, and this subtype generally overexpresses EGFR.
Sensitivity to three EGFR inhibitors (cetuximab, gefitinib and lapatinib, an HER2/EGFR-TK inhibitor) was evaluated in a
metastatic TNBC cell model (MDA-MB-231), and the impact of these drugs on the activity and stability of HIF was assessed.
Methodology/Principal Findings: MDA-MB-231 cells were genetically modified to stably express an enhanced green
fluorescent protein (EGFP) induced by hypoxia; the Ca9-GFP cell model reports HIF activity, whereas GFP-P564 reports HIF
stability. The reporter signal was monitored by flow cytometry. HIF-1 DNA-binding activity, cell migration and viability were
also evaluated in response to EGFR inhibitors. Cell fluorescence signals strongly increased under hypoxic conditions (. 30-
fold). Cetuximab and lapatinib did not affect the signal induced by hypoxia, whereas gefitinib sharply reduced its intensity
in both cell models and also diminished HIF-1 alpha levels and HIF-1 DNA-binding activity in MDA-MB-231 cells. This
gefitinib feature was associated with its ability to inhibit MDA-MB-231 cell migration and to induce cell mortality in a dose-
dependent manner. Cetuximab and lapatinib had no effect on cell migration or cell viability.
Conclusion: Resistance to cetuximab and lapatinib and sensitivity to gefitinib were associated with their ability to modulate
HIF activity and stability. In conclusion, downregulation of HIF-1 through EGFR signaling seems to be required for the
induction of a positive response to EGFR-targeted therapies in TNBC.
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Introduction
Recently, breast carcinomas have been classified into the
following clinicopathological subtypes based on molecular profil-
ing: luminal, human epidermal growth factor receptor (HER2)
overexpressing, normal-like, and basal-like breast cancers (BLBCs)
[1]. BLBCs express basal markers such as cytokeratins and
epidermal growth factor receptor (EGFR) and are generally
negative for HER2 expression and both the progesterone and
estrogen receptors [2,3,4]. This breast cancer subtype is also called
triple-negative breast cancer (TNBC) and represents about 15% of
invasive breast carcinomas. TNBC does not respond to hormonal
therapy (such as tamoxifen or aromatase inhibitors) or HER2-
targeted therapies such as Herceptin (trastuzumab). TNBC shows
an aggressive pattern of progression with a high rate of early-
occurring metastasis [5]. TNBC is one of the most challenging
subtypes of invasive breast cancer to treat because of the lack of
specific therapies. However, as mentioned previously, EGFR
expression is seen in a majority of TNBC cases, thus providing a
potential targeted therapy [6].
EGFR is a tyrosine kinase receptor that triggers the phospha-
tidylinositol 3-kinase (PI3K)/Akt pathway upon activation [7]. In
many human cancers, such as colorectal cancer and non-small-cell
lung cancer, EGFR overexpression is correlated with cellular
proliferation, angiogenesis and tumor growth, leading to disease
progression involving invasion and metastasis [8]. Epidermal
growth factor (EGF) has been shown to stimulate the migration of
breast [9], prostate [10] and renal carcinoma cells [11]. Clinical
studies have shown that patients with brain metastasis are prone to
have primary tumors that are hormone receptor negative and
overexpress HER2 and/or EGFR [12]. Furthermore, EGF can
promote the migration of a TNBC cell line (MDA-MB-231)
through the PI3K/Akt pathway, suggesting that EGF may be
involved in breast cancer progression [13].
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to treat advanced cancers by disrupting PI3K/Akt signaling
cascades and circumventing the development of metastasis [14].
Different approaches have been used to target EGFR, including
small molecules such as ZD1839/gefitinib (Iressa) or GW572016/
lapatinib (Tyverb) and humanized monoclonal antibodies such as
cetuximab (Erbitux). Gefitinib is a selective EGFR tyrosine kinase
inhibitor, and lapatinib is a dual inhibitor of EGFR and HER2
tyrosine kinase activity. However, evidence of resistance to these
drugs has been described, with hypoxia in solid tumors being a
putative causative factor. Hypoxic tumors are characterized by
more aggressive and metastatic phenotypes, with lower sensitivity
to treatments, leading to poor prognosis [15,16].
Oxygen homoeostasis plays a central role in the development
and growth of tissues. In solid tumors, cells within the tumor have
to adapt their metabolism to the low availability of oxygen by
increasing the expression of genes involved in processes such as
angiogenesis, erythropoiesis, glucose metabolism, cell survival and
cell proliferation. Gene transcription is regulated by a transcription
factor called hypoxia-inducible factor 1 (HIF-1) [17,18]. The HIF-
1 protein is heterodimeric, composed of an alpha subunit and a
beta subunit that are constitutively expressed under normoxia.
However, HIF-1 alpha is rapidly degraded and cannot be detected
in cells [19]. HIF-2 alpha is another isoform of the alpha subunit
with similar structure. HIF-1 alpha was the first isoform identified
and is ubiquitously expressed [20]. HIF-1 alpha is targeted for
degradation through the hydroxylation of its oxygen-dependent
degradation domain (ODDD) by 2-oxoglutarate-dependent diox-
ygenases, which are prolyl hydroxylases (PHDs). These enzymes
use oxygen as a cofactor and hydroxylate two conserved proline
residues (Pro402 and Pro564) in the ODDD [21]. Prolyl-
hydroxylated HIF-1 alpha is recognized by the Von Hippel-
Lindau protein (pVHL), which is a component of an E3 ubiquitin
ligase complex that drives polyubiquitylation and proteasomal
degradation [22,23]. In addition, an asparagyl hydroxylase called
factor inhibiting HIF-1 (FIH-1) hydroxylates asparagine 803 in the
C-terminal transactivation domain (CAD), thus preventing HIF-1
alpha from interacting with transcriptional coactivators such as
p300 [24]. Under hypoxic conditions, HIF-1 alpha is stabilized
and accumulates because of the inactivation of dioxygenases. HIF-
1 alpha is translocated to the nucleus where it associates with HIF-
1 beta. HIF-1 binds to hypoxia-responsive elements (HRE), which
are specific sequences (59-RCGTG-39) in the promoter regions of
target genes, allowing transcriptional activation [25].
The PI3K/Akt signaling cascade also regulates HIF-1 alpha
protein levels in an oxygen-independent manner via the mamma-
lian target of rapamycin (mTOR) [26]. In this way, HIF-1 alpha
synthesis is upregulated in response to EGFR activation [27,28].
Anti-EGFR-targeted therapies may decrease the hypoxia-induced
accumulation of HIF-1, leading to a reduction in HIF-1-mediated
drug resistance and metastasis through the inhibition of EGFR
signaling. In this study, the effects of three EGFR inhibitors
(gefitinib, lapatinib and cetuximab) on the stability and activity of
hypoxia-induced factors have been evaluated in a metastatic basal-
like TNBC model (MDA-MB-231). We also assessed the effects of
these drugs on cell migration and cell viability.
Results
Stable fluorescent mammary cell lines for examining
responses to hypoxia
To estimate the transcriptional activity of HIF complexes and the
stability of HIF alpha isoforms, two EGFP-labeled cell lines were
engineered from the metastatic TNBC cell line MDA-MB-231. A
clonalpopulationofMDA-MB-231 cellswas transfectedwithone of
two plasmids coding for EGFP. The fluorescent signal of the cells
was activated by hypoxia through the Ca9 promoter in the Ca9-
GFP cell model and via the stability of EGFP in the GFP-P564 cell
model (Fig. 1). The transfected cell populations were characterized
by fluorometry, flow cytometry and microscopy. The most
homogenous clones with the highest fluorescence intensity were
selected. Stability was assessed by measuring fluorescence after
variousnumbersofpassages and freeze-thaw cycles and the removal
of antibiotic selection pressure. Fluorescent proteins were chosen for
these models as, unlike luminescent systems using luciferase, they do
not consume molecular oxygen, and therefore, the induction
process is unbiased and more physiologically relevant. Cellular
phenotypes were determined by flow cytometry. Forward and side
scatter signals were used to limit the analysis to viable cells. Cell
counts (y axis) were plotted against the EGFP signal (x axis). EGFP-
negative cells were used to set the photomultiplicator (PM)
amplification and background signals (Fig. 2).
EGFP fluorescence in the Ca9-GFP and GFP-P564 models
strongly increased in the presence of hypoxia-mimicking reagents
(Co, DFO and DMOG) and under hypoxia (1% O2). In both cell
models, induction was stronger in the presence of the mimetic
compounds compared with hypoxia. EGFP was induced up to 40-
fold in GFP-P564 cells treated with 200 mM DFO for 24 H and
35-fold in Ca9-GFP cells (Fig. 3A). As shown in time-course
experiments (Fig. 3B), induction in response to 200 mM DFO was
detected at a significant level only after 20 H. Treatment with
DFO also induced a dose-dependent increase in cellular
fluorescence (Fig. 3C). This was correlated with the endogenous
level of HIF-1 alpha protein in MDA-MB-231 cells. HIF-1 alpha
levels, measured by whole-cell ELISA, significantly increased
under DFO and hypoxic conditions (Fig. 3D). Furthermore, HIF-1
alpha expression and DNA-binding activity, as assessed in nuclear
extracts, were also induced by DFO and hypoxia (Fig. 3E-F).
Figure 1. Diagrams depicting the GFP-P564 and Ca9-GFP
molecular construct. (A) The GFP-P564 construct encodes a fusion
protein in which EGFP is fused to a peptide containing the Pro564
residue of the HIF alpha subunit. This residue is hydroxylated under
normoxic conditions, allowing it to be recognized by pVHL and
degraded by the proteasome pathway. Under hypoxic conditions, the
peptide is not degraded, and the EGFP fusion protein is continuously
expressed under the control of the CMV promoter. This construct
reports the post-translational stability of HIF alpha subunits. (B) In the
Ca9-GFP cell model, EGFP is activated by HIF dimers under hypoxic
conditions. HIF complexes bind to the Ca9 promoter resulting in EGFP
expression, which can be detected by flow cytometry. Under normoxic
conditions, HIF alpha subunits are continuously degraded, and Ca9-GFP
cells do not fluoresce. This model reports the transcriptional activity of
HIF complexes.
doi:10.1371/journal.pone.0025080.g001
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reporter clones in terms of their capacity for induction by hypoxia
and mimetic compounds targeting dioxygenases, which have been
implicated in the regulation of hypoxia responses. Time- and dose-
dependent effects were also observed. The induction of EGFP
followed HIF-1 alpha protein expression and consensus HRE
DNA binding. The Ca9-GFP and GFP-P564 cell lines constituted
attractive models of metastatic basal-like TNBC in which to study
hypoxia signaling during in vitro drug assays.
Effect of EGFR-targeted therapies on the hypoxia-
induced stability and activity of HIF-1 alpha
The overexpression of membrane EGFR, low expression of
HER2 receptor and migratory ability were verified in MDA-MB-
231 parental cells and the Ca9-GFP and GFP-P564 cell lines using
immunocytochemistry and migration assays (data not shown). We
examined the effects of EGFR-targeted therapies on the hypoxia-
induced stability and activity of HIF complexes. Cetuximab and
the two EGFR tyrosine kinase inhibitors (lapatinib and gefitinib)
did not affect the signal intensity in either cell model under
normoxia. Stimulation with DFO was not influenced by
cetuximab or lapatinib treatment, whereas gefitinib strongly
reduced the fluorescence by approximately 10-fold (Fig. 4A).
The effect of gefitinib was confirmed in the presence of DMOG
and under hypoxia (Fig. 4B-C), suggesting that gefitinib reduced
the stabilization of HIF alpha isoforms and the activity of HIF
dimers through the EGFR signaling pathway. The ability of
gefitinib to inhibit the reporter signal was also partially observed in
the presence of the proteasome inhibitor MG132, either alone or
when combined with DFO (Fig. 4D). This inhibitory effect was
more pronounced in Ca9-GFP cells than in GFP-P564 cells.
None of the three therapies affected fluorescence in the CMV-
GFP cell model that constitutively expressed EGFP, indicating the
Figure 2. Flow cytometric analysis of EGFP fluorescence in
GFP-P564 and Ca9-GFP cells. Cells were treated with 250 mM
desferioxamine (DFO) for 24 H or left untreated. R1 is the region of
fluorescence induced by DFO. The percentage of cells in R1 and the
mean fluorescence increased in response to hypoxic conditions.
doi:10.1371/journal.pone.0025080.g002
Figure 3. Validation of the GFP-P564 and Ca9-GFP hypoxia-inducible reporters. Hypoxic stimuli induced HIF-1 alpha accumulation in
MDA-MB-231 cells and increased fluorescence in the GFP-P564 and Ca9-GFP cell models. Cells were treated with 200 mM cobalt (Co), 200 mM DFO, or
1 mM dimethyloxalylglycine (DMOG) or exposed to 1% O2 for 24 H (hx). Untreated cells were incubated under normoxic conditions (nx) and used as
controls. (A) Fluorescence was evaluated by flow cytometry, and the signal significantly increased (p,0.05) under hypoxic conditions. DFO induced
(B) time- and (C) dose-dependent fluorescence, as assessed by flow cytometry in GFP-P564 and Ca9-GFP cells. (D) Total HIF-1 alpha was quantified in
whole MDA-MB-231 cells using an ELISA assay. (E) HIF-1 alpha protein levels in MDA-MB-231 cells were analyzed by western blot. (F) HIF-1 alpha DNA-
binding activity was analyzed in MDA-MB-231 nuclear extracts using a 96-well ELISA assay; the absorbance was assessed at 450 nm. Each well was
coated with a dsDNA sequence containing the HIF-1 alpha response element. The data represent three independent experiments (average mean 6
SEM).
doi:10.1371/journal.pone.0025080.g003
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chromophore. Moreover, the construct specificities of the Ca9-
GFP and GFP-P564 models were established that way (Fig. 4E).
To confirm the observed variation detected by the fluorescent
reporters in response to drug treatment under hypoxia, HIF-1
alpha levels were quantified by ELISA in MDA-MB-231 cells.
Treatment with cetuximab and lapatinib did not produce any
change in HIF-1 alpha expression under normoxia or hypoxic
conditions, whereas gefitinib significantly reduced HIF-1 alpha
induction in response to DFO and hypoxia (Fig. 5A). DNA-
binding assays were also assessed under hypoxia and in the
presence of MG132. HIF-1 alpha bound to a consensus HRE was
detected using a specific antibody. DNA-binding activity mediated
by hypoxia and MG132 only decreased in response to gefitinib
Figure 4. Effect of EGFR inhibitors on hypoxia-induced responses in GFP-P564 and Ca9-GFP cells. Cells were treated with 75 mg/mL
cetuximab (cx), 10 mg/mL lapatinib (lp) or 10 mg/mL gefitinib (gf) under hypoxic conditions and stimulated with 200 mM DFO, 5 mM MG132 or 1 mM
DMOG or exposed to 1% O2 (hx) for 24 H. Fluorescence intensity was assessed by flow cytometry. As controls (ct), cells were incubated under
normoxic conditions and left untreated. (A) Cetuximab and lapatinib did not affect the induction of fluorescence by DFO, whereas gefitinib
suppressed it in both models. (B-C) Gefitinib also inhibited the induction of fluorescence in GFP-P564 and Ca9-GFP cells in the presence of DMOG and
under hypoxia. (D) MG132 is a proteasome inhibitor that induces the stabilization of HIF-1 alpha. Gefitinib diminished the MG132-mediated
stabilization of HIF-1 alpha. (E) Cetuximab, lapatinib and gefitinib did not affect the constitutive fluorescence of MDA-MB-231 cells transfected with
pEGFP-C1 (CMV-GFP model). Data are shown as the mean 6 SEM (n=3). Statistical differences were assessed using unpaired t-tests; p,0.05 was
considered to be significant (* p,0.05).
doi:10.1371/journal.pone.0025080.g004
Figure 5. Effect of EGFR inhibitors on HIF-1 alpha in MDA-MB-231 cells under hypoxic conditions. Cells were treated with 75 mg/mL
cetuximab (cx), 10 mg/mL lapatinib (lp) or 10 mg/mL gefitinib (gf) under normoxia or hypoxia and stimulated with DFO or MG132 for 24 H. Controls
(ct) were left untreated. (A) Total HIF-1 alpha was detected with a whole-cell ELISA assay. Only gefitinib prevented HIF-1 alpha induction by DFO or
hypoxia. (B) HIF-1 alpha levels were quantified in nuclear extracts with a DNA-binding assay. Gefitinib reduced the HIF-1 alpha nuclear accumulation
induced by hypoxia and MG132. The results are from three independent experiments, and the bars represent the SEM. Student’s t-tests were
performed to compare the drug responses according to the hypoxia conditions (* p,0.05).
doi:10.1371/journal.pone.0025080.g005
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induced stabilization and transcriptional activity of HIF-1 could be
reversed through EGFR inhibition by selected EGFR-targeted
therapies.
Differential effects of EGFR-targeted therapies on the
viability and migratory response of MDA-MB-231 cells
We showed that hypoxia-induced HIF stabilization and activity
decreased after gefitinib treatment. Next, we evaluated the
migratory response to EGFR inhibitors. Boyden chamber assays
or transwell assays using 8-mm filters were assessed under
normoxic and hypoxic conditions for 24 H. Under normoxia,
9069% of untreated cells migrated, whereas only 4664%
migrated under hypoxia. Neither cetuximab nor lapatinib affected
cell motility in either condition. In contrast, gefitinib abolished
MDA-MB-231 cell migration, even when viability was taken into
account. The migratory response was reduced from 9069% to
262% under normoxia and from 4664% to 562% when the cells
were exposed to hypoxia (Fig. 6A). We also investigated the
sensitivity of the cells to treatment with EGFR inhibitors using
calcein-AM staining for viable cells under normoxia. Exposure to
increasing concentration of cetuximab and lapatinib did not alter
cell viability, whereas gefitinib dramatically induced cell mortality
in a dose-dependent manner (IC50=1462.1 mg/mL) (Fig. 6B).
Similar results were obtained with the CMV-GFP cell line under
normoxia (data not shown) and under hypoxia (Fig. 6C).
Discussion
TNBC frequently overexpresses EGFR, and this feature
represents a promising potential therapeutic target. The EGFR
pathway can be targeted by i) an anti-EGFR monoclonal antibody
that binds to the extracellular domain of EGFR, such as cetuximab,
ii) tyrosine kinase inhibition at the intracellular level, either by a
specific inhibitor, such as by gefitinib, which blocks the tyrosine
kinase activity of the EGFR intracellular domain, or by an inhibitor
with dual specificity, such as lapatinib, a HER2 and EGFR tyrosine
kinase inhibitor. Both classes of therapy inhibit the signal
transduction of EGFR and are approved for many advanced
cancers. However, these therapies benefit only a small proportion of
patients. For non-small-cell lung cancer, the population approved
for gefitinib is defined by the presence of specific EGFR mutations
[29], whereas for colorectal cancer, patients with KRAS mutations
are excluded from treatment by cetuximab [30]. Even in those
selected population more than half of the patients will not benefit
from treatment or will develop resistance. EGFR mutations and
KRAS mutations either do not occur or are exceptional in breast
cancer.Forbreastcancer,lapatinibisindicated foradvanced HER2
breast cancer. A potential mechanism of resistance to cancer
treatment is linked to the hypoxic tumor microenvironment.
Cellular adaptations to hypoxia are mainly mediated by HIF-1
alpha accumulation. In breast cancer, the overexpression of HIF-1
alpha is associated with increased mortality [31]. In addition to
tumor hypoxia, genetic alterations also can increase HIF-1 alpha
levels. Indeed, it has been demonstrated that gain-of-function
mutations in oncogenes such as HER2 or EGFR and loss-of-
function mutations in tumor-suppressor genes such as VHL or
PTEN induce HIF-1 activity [28,32,33]. Activation of the PI3K/
Akt pathway stimulates HIF-1 alpha protein synthesis through
EGFR signaling[27,34],andseveral studieshave shown that EGFR
inhibitors decrease HIF-1 alpha expression in various tumor cell
lines [35]. HIF-1 targets genes involved in drug resistance and
processessuch as extracellularmatrix metabolism and cell adhesion,
leading to invasion and metastasis. However, the exact mechanism
that links HIF-1 to these processes has not yet been elucidated.
Furthermore, it seems that this mechanism differs depending upon
the cell type considered.
Although basal-like TNBC cell lines express EGF receptor,
resistance to anti-EGFR therapies has also been described [5]. To
Figure 6. Effect of anti-EGFR-targeted therapies on MDA-MB-
231 cell migration and viability. (A) Cells were treated with 75 mg/
mL cetuximab (cx), 10 mg/mL lapatinib (lp) or 10 mg/mL gefitinib (gf)
and allowed to migrate through inserts (8 mm) under normoxia and
hypoxia (1% O2) for 24 H. Cell migration is expressed as the percentage
of unmigrated cells. Only gefitinib inhibited MDA-MB-231 cell migration
under both conditions. (B) Cells were treated with increasing
concentrations of cetuximab (C0:0, C1:25, C2:75, C3:100, C4:150 mg/
mL), lapatinib and gefitinib (C0:0, C1:3, C2:10, C3:20, C4:40 mg/mL)
under normoxic conditions. Viability was assessed using green calcein-
AM labeling and fluorometry (ex: 490/em: 520 nm). Cetuximab and
lapatinib did not affect cell viability, whereas gefitinib induced mortality
in a dose-dependent manner. (C) A viability assay was performed in a
96-well plate by measuring drug effects under hypoxia in a CMV-GFP
cell model that constitutively expressed EGFP. The fluorescence of each
well was measured by fluorometry (ex: 488/em: 507 nm), and the signal
intensity was proportional to the number of viable cells. Gefitinib
strongly induced mortality. The results are representative of at least
three independent experiments. Statistical significance was determined
by unpaired t-test between treated cells and controls (* p,0.05).
doi:10.1371/journal.pone.0025080.g006
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expression systems based on the triple-negative MDA-MB-231 cell
line. The GFP-P564 cell model reports the post-translational
stability of HIF-1 alpha. The peptide fused in frame with EGFP in
this cell model contains HIF-1 alpha amino acids 548 to 583.
Hydroxylation of Pro564 has been identified as essential for HIF-1
alpha binding to pVHL, leading to ubiquitin-mediated proteaso-
mal degradation [21,23]. Furthermore, the interaction between
pVHL and HIF-1 alpha has been shown to be dependent on a 27-
residue segment comprising residues 549–575 that are highly
conserved between different HIF alpha isoforms and also between
HIF-1 alpha homologs from human and nonhuman species [36].
Ca9-GFP cells report the transcriptional activity of HIFs through
an EGFP reporter under the control of the Ca9 promoter. The
expression of Ca9 is strongly induced by hypoxia in many human
cancers [37]. The organization of the Ca9 promoter with the HRE
immediately upstream of the transcription start enables tight
regulation by HIF-1 and suggests that Ca9 would be an excellent
hypoxic marker in cancers [38,39]. The native promoter of the
Ca9 gene represents a fine sensor for the transcriptional activation
of HIF because the HRE motif plays a crucial role in gene
regulation [39,40]. Moreover, it has been shown that Ca9 is also
regulated in an oxygen-independent manner through the PI3K
pathway [41]. Thus, these cell models allowed the potential effects
of cetuximab, lapatinib and gefitinib on responses to hypoxia to be
assessed. Cetuximab and lapatinib had no effect on hypoxia-
induced fluorescence signals in either cell model and did not affect
HIF-1 alpha expression in MDA-MB-231 cells. In contrast,
gefitinib treatment downregulated HIF-1 alpha and sharply
decreased the reporter signal intensity under hypoxia and in the
presence of DFO or DMOG. We also observed this effect of
gefitinib when the ubiquitin-proteasome pathway was simulta-
neously blocked by a proteasome inhibitor (MG132) and a PHD
inhibitor (DFO). These results suggest that this repression is due, in
part, to a mechanism independent of the PHD/VHL/proteasome
mechanism. Repression of HIF activity, as seen in Ca9-GFP cells,
is consistent with an enhancement of HIF-1 alpha mRNA
translation due to AKT/mTOR activation, leading to increased
levels of HIF proteins [26,27,28]. However, this does not explain
the results observed in the GFP-P564 cells.
A differential effect of the EGFR inhibitors on the viability and
migration of the TNBC cell line was demonstrated, with these cells
being resistant to cetuximab and lapatinib and sensitive to gefitinib
at high concentrations. Viability data for cetuximab and gefitinib
were consistent with previous observations made using a
proliferation assay in the same breast cell line [6]. These
differences were correlated with the modulation of HIF expression,
stability, DNA-binding capacity and activation under hypoxia.
The ability to reduce the hypoxia–induced expression of HIF-1
alpha would be necessary for a positive response of TNBC cells to
EGFR-targeted therapy. Several studies have demonstrated that
cellular sensitivity to cetuximab and gefitinib required HIF-1 alpha
to be downregulated [42,43,44]. It has already been suggested that
HIF-1 alpha could be a novel response marker for EGFR
inhibitors in cancer cell lines that overexpressed EGFR [43]. We
also reported here that hypoxia reduced the ability of MDA-MB-
231 cells to migrate, regardless of their endogenous HIF-1 alpha
status, whereas hypoxia in tumors has been shown to promote
invasion and metastasis [45]. Our results were consistent with the
observation that MDA-MB-231 cell migration varied depending
on the oxygen concentration. Exposure to 1 or 2% O2 could
reduce MDA-MB-231 cell migration, whereas 5% O2 strongly
enhanced cell migration [46]. We demonstrated that only gefitinib
inhibited cell migration under normoxic and hypoxic conditions.
This effect was correlated with the downregulation of hypoxia-
induced HIF-1 alpha. Fujiwara et al. reported that downregulation
of HIF-1 alpha expression could reduce the migration and
invasion of some cancer cell lines in vitro [47]. Recently, Li et al.
examined the migration of a HIF-1 alpha knockout cell line and
reported an inhibition of cell motility compared with wild type
cells [48].
To our knowledge, this is the first report describing the
differential effects of three EGFR inhibitors on the viability and
migration of a TNBC cell line. Downregulation of HIF-1 alpha
through the EGFR signaling pathway appeared to be necessary for
inducing a positive response to EGFR-targeted therapies, although
this may not be sufficient. These results suggest that the activity of
HIF-1 alpha in response to EGFR inhibitors will be of interest in
preclinical and clinical studies.
Materials and Methods
Cell culture and hypoxic conditions
Human MDA-MB-231 metastatic breast carcinoma cells were
obtained from the American Type Culture Collection (Manassas,
VA, USA). These cells are HER2 negative, estrogen- and
progesterone-receptor negative, and overexpress EGFR. Cells
were maintained in monolayer culture in a 5% CO2 incubator at
37uC in RPMI 1640 medium (Invitrogen Life Technologies,
Carlsbad, CA, USA) supplemented with 10% fetal bovine serum,
2 mM L-glutamine and 20 mg/mL gentamicin. To establish
hypoxic conditions, cells were plated in 12-well tissue culture
plates and placed in a hypoxic chamber (O2sensBox, Adelbio,
Clermont-Ferrand, France) flushed with a 1%O2/5%CO2/
94%N2 gas mixture for 24 H at 37uC. Alternatively, cells were
treated with hypoxia-mimetic compounds for 24 H. Cobalt
chloride (CoCl2), dimethyloxalylglycine (DMOG) and the iron
chelator desferrioxamine (DFO) mimic the effects of hypoxia by
inducing HIF-1 alpha, and MG132 is a proteasome inhibitor.
CoCl2, DMOG, MG132 and DFO were obtained from Sigma-
Aldrich (St Louis, MO, USA). With the exception of those used for
the dose-response experiments, cells were treated with 200 mM
CoCl2, 200 mM DFO or 1 mM DMOG for 24 H.
Drug preparation and treatment
Lapatinib and gefitinib were purchased from LC Laboratories
(Woburn, MA, USA). They were dissolved in PBS and stored at
220uC. Cetuximab was supplied by Merck Pharma (Darmstadt,
Germany). Cells were treated with increasing concentrations of
these drugs under hypoxic and normoxic conditions for 24 H.
Measurement of HIF-1 alpha protein by ELISA
MDA-MB-231 cells were plated in 96-well plates (10 000 cells
per well) and treated with cetuximab (75 mg/mL), lapatinib and
gefitinib (10 mg/mL) for 24 H under normoxic and hypoxic
conditions (DFO and hypoxia). Conditioned medium was then
collected and the cells were fixed and permeabilized with 4%
formaldehyde. HIF-1 alpha levels were determined from whole-
cell lysates using a human total-HIF-1 alpha Cell-Based ELISA kit
according to the manufacturer’s protocol (R&D Systems, Minne-
apolis, MN, USA). Briefly, cells were simultaneously incubated
with two primary antibodies, anti-HIF-1 alpha and anti-cyto-
chrome C (normalization antibody). Two labeled secondary
antibodies and two fluorogenic substrates were used for detection.
Total HIF-1 alpha fluorescence (ex: 540 nm/em: 600 nm) was
normalized to the fluorescence of cytochrome C (ex: 360 nm/em:
450 nm).
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MDA-MB-231 cells were treated with cetuximab, lapatinib and
gefitinib, as indicated previously, under normoxia and hypoxia.
An assay with gefitinib was also performed in the presence of
MG132 (5 mg/mL). HIF-1 alpha binding was assessed using
Cayman’s HIF-1 alpha transcription factor assay (Cayman
Chemicals, Ann Arbor, MI, USA). Briefly, a double-stranded
oligonucleotide that contained a consensus HIF-1 alpha binding
site was immobilized in each well of a 96-well plate and incubated
with nuclear extracts (50 mg/well) for 30 minutes at room
temperature. The plate was washed and incubated with a primary
anti-HIF-1 alpha antibody. A secondary antibody conjugated with
horseradish peroxidase (HRP) was used for detection. The DNA-
binding activity of HIF-1 alpha was measured by absorbance and
was expressed as the optical density at 450 nm (OD450). This kit
used a positive control for HIF-1 alpha activation and a specific
competitor dsDNA for HIF-1 binding to the plate to monitor the
specificity of the assay.
Western blot analysis
Nuclear extracts were obtained with a nuclear extraction kit
(Cayman chemicals), and protein concentrations were determined
using a bicinchoninic acid assay kit (Bio-Rad Laboratories,
Hercules, CA, USA). Each sample (50 mg) was separated by
electrophoresis on a 12% SDS-polyacrylamide gel, and the
proteins were transferred onto a nitrocellulose membrane (Bio-
Rad Laboratories). The membrane was blocked in 5% milk in
Tris-buffered saline with 0.1% Tween (TBST) at 4uC for one hour
and incubated under mild agitation with a monoclonal anti-HIF-1
alpha antibody (Novus Biologicals, Littleton, CO, USA) diluted
1:1500 at 4uC overnight. Membranes were washed three times in
TBST and incubated for one hour with an HRP-conjugated
secondary antibody (diluted 1:2000), and detection was performed
using an enhanced chemiluminescence detection system (GE
Healthcare, Piscataway, NJ, USA).
DNA constructs
The GFP-P564 DNA construct encodes a peptide containing the
Pro564 residue of human HIF-1 alpha (Genbank accession
number: U22431) fused in-frame to the 39 end of the enhanced
green fluorescent protein (EGFP) in a pEGFP-C1 vector
(Clontech, Mountain View, CA, USA). This peptide is encoded
by a 135-bp DNA fragment corresponding to amino acids 543-587
of human HIF-1 alpha. PEGFP-C1 is a plasmid coding for EGFP
driven by a human cytomegalovirus promoter (CMV). The Ca9-
GFP DNA construct was obtained by integrating the sequence
between 2522 and +9 from the transcriptional start site of the
carbonic anhydrase 9 (Ca9) promoter (Genbank accession number:
NM_001216) into a pEGFP-1 vector (Clontech).
Stable transfection
The GFP-P564 and Ca9-GFP cell lines were obtained by the
stable transfection of MDA-MB-231 cells with the molecular
constructs described above using the Fugene-6 reagent kit (Roche,
Mannheim, Germany). The medium was removed 24 hours after
transfection, and the cells were supplemented with complete media
containing 600 mg/ml of G418 (Invitrogen) for selection for 3
weeks; the cells were subsequently grown in the presence of
100 mg/mL G418. Stable GFP-P564 and Ca9-GFP cells were
cloned by limiting dilution, and reporter expression was
determined by flow cytometry (Beckman Coulter, Miami, FL,
USA) in cells exposed to 200 mM DFO and 1 mM DMOG for 24
H, in order to select hypoxia-inducible clones. EGFP has
excitation and emission maxima at 488 nm and 507 nm,
respectively. A clone transfected with an empty pEGFP-C1 vector
that constitutively expressed EGFP (CMV-GFP) was used as
control for the GFP-P564 and Ca9-GFP experiments. Direct
sequencing was used to verify the authenticity of each construct
before and after the transfection assay.
Cell migration assay
MDA-MB-231 cell migration was assessed using a modified
Boyden chamber method with a 24-well plate. The filter was a
polyethylene terephthalate membrane with 8-mm pores (Millipore,
Billerica, MA, USA). Briefly, cell suspensions were seeded into the
upper chamber of the inserts (10 000 cells per well), and the inserts
were placed into a well that contained conditioned media. Cells
were treated with 75 mg/mL cetuximab, 10 mg/mL lapatinib and
10 mg/mL gefitinib under normoxia or hypoxia for 24 H. Non-
migrating cells were removed by gentle scraping and were counted
using trypan blue (Invitrogen). The migratory responses to EGFR
inhibitors were quantified by the percentage of cells that migrated.
Triplicate wells were analyzed in each assay, and the assay was
repeated at least three times.
Cell viability assay
A fluorogenic esterase substrate (Calcein-AM, Sigma-Aldrich)
was used to investigate cell viability under hypoxia in response to
EGFR inhibitors. Cells were seeded in black-walled microplates
and treated with 5 mM of Calcein-AM for one hour at 37uC.
Viability was determined by measuring fluorescence using a
490 nm excitation filter and a 520 nm emission filter. The
fluorescence intensity was assumed to be proportional to the
number of viable cells. The effect of the drugs was also analyzed
under normoxia with a CMV-GFP cell line that constitutively
expressed EGFP. Cells were seeded on a 96-well plate, and at 80–
90% confluence, the cells were treated with increasing concentra-
tions of EGFR inhibitors. After washing with PBS, the signal
intensity of each well was quantified by fluorometry (ex: 488 nm/
em: 507 nm).
Statistical Analysis
All experiments were repeated at least 3 times. All data are
presented as the mean 6 SEM. An unpaired Student’s t-test was
used to compare the treated and control groups. A probability
value p,0.05 was considered significant.
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